Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis

被引:68
作者
Lima, KM
Santos, SA
Lima, VMF
Coelho-Castelo, AAM
Rodrigues, JM
Silva, CL
机构
[1] Univ Sao Paulo, Dept Biochem & Immunol, Sch Med Riberiao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
[2] Sao Paulo State Univ, Sch Vet Med, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
DNA vaccines; TDM; hsp65; microspheres; PLGA; tuberculosis;
D O I
10.1038/sj.gt.3301908
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The high incidence of tuberculosis around the world and the inability of BCG to protect certain populations clearly indicate that an improved vaccine against tuberculosis is needed. A single antigen, the mycobacterial heat shock protein hsp65, is sufficient to protect BALB/c mice against challenge infection when administered as DNA vaccine in a three-dose-based schedule. In order to simplify the vaccination schedule, we coencapsulated hsp65-DNA and trehalose dimicolate (TDM) into biodegradable poly(DL-lactide-co-glycolide) (PLGA) microspheres. BALB/c mice immunized with a single dose of DNA-hsp65/TDM-1oaded microspheres produced high levels of IgG2a subtype antibody and high amounts of IFN-gamma in the supernatant of spleen cell cultures. DNA-hsp65/TDM-loaded microspheres were also able to induce high IFN-gamma production in bulk lung cells from challenged mice and confer protection as effective as that attained after three doses of naked DNA administration. This new formulation also allowed a ten-fold reduction in the DNA dose when compared to naked DNA. Thus, this combination of DNA vaccine and adjuvants with immunomodulatory and carrier properties holds the potential for an improved vaccine against tuberculosis.
引用
收藏
页码:678 / 685
页数:8
相关论文
共 30 条
[1]   DNA vaccination: Transfection and activation of dendritic cells as key events for immunity [J].
Akbari, O ;
Panjwani, N ;
Garcia, S ;
Tascon, R ;
Lowrie, D ;
Stockinger, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (01) :169-177
[2]  
BERSA GS, 1994, TUBERCULOSIS PATHOGE, P285
[3]   Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice [J].
Bonato, VLD ;
Lima, VMF ;
Tascon, RE ;
Lowrie, DB ;
Silva, CL .
INFECTION AND IMMUNITY, 1998, 66 (01) :169-175
[4]   Enhanced response to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction [J].
Boyle, JS ;
Brady, JL ;
Lew, AM .
NATURE, 1998, 392 (6674) :408-411
[5]   RECENT ADVANCES ON THE USE OF BIODEGRADABLE MICROPARTICLES AND NANOPARTICLES IN CONTROLLED DRUG-DELIVERY [J].
BRANNONPEPPAS, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 116 (01) :1-9
[6]   Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells [J].
Doe, B ;
Selby, M ;
Barnett, S ;
Baenziger, J ;
Walker, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8578-8583
[7]   BIODEGRADABLE MICROSPHERES AS A VACCINE DELIVERY SYSTEM [J].
ELDRIDGE, JH ;
STAAS, JK ;
MEULBROEK, JA ;
MCGHEE, JR ;
TICE, TR ;
GILLEY, RM .
MOLECULAR IMMUNOLOGY, 1991, 28 (03) :287-294
[8]   Driving a stake into resurgent TB [J].
Enserink, M .
SCIENCE, 2001, 293 (5528) :234-235
[9]   A proposed national strategy for tuberculosis vaccine development [J].
Ginsberg, AM .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S233-S242
[10]   Genetic vaccines: Strategies for optimization [J].
Gregoriadis, G .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :661-670